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Abstract
Background Psoriatic arthritis (PsA) is a challenging heterogeneous disease. The European League Against Rheumatism (EULAR)
and the Group for Research and Assessment of Psoriasis and PsA (GRAPPA) last published their respective recommendations for the
management of PsA in 2015. However, these guidelines are primarily based on studies conducted in resource replete countries andmay
not be applicable in countries in the Americas (except Canada andUSA) and Africa.We sought to adapt the existing recommendations
for these regions under the auspices of the International League of Associations for Rheumatology (ILAR).
Process The ADAPTE Collaboration (2009) process for guideline adaptation was followed to adapt the EULAR and GRAPPA
PsA treatment recommendations for the Americas and Africa. The process was conducted in three recommended phases: set-up
phase; adaptation phase (defining health questions, assessing source recommendations, drafting report), and finalization phase
(external review, aftercare planning, and final production).
Result ILAR recommendations have been derived principally by adapting the GRAPPA recommendations, additionally,
EULAR recommendations where appropriate and supplemented by expert opinion and literature from these regions. A paucity
of data relevant to resource-poor settings was found in PsA management literature.
Conclusion The ILAR Treatment Recommendations for PsA intends to serve as reference for the management of PsA in the
Americas and Africa. This paper illustrates the experience of an international working group in adapting existing recommenda-
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tions to a resource-poor setting. It highlights the need to conduct research on the management of PsA in these regions as data are
currently lacking.
Key Points
• The paper presents adapted recommendations for the management of psoriatic arthritis in resource-poor settings.
• The ADAPTE process was used to adapt existing GRAPPA and EULAR recommendations by collaboration with practicing clinicians from the
Americas and Africa.
• The evidence from resource-poor settings to answer clinically relevant questions was scant or non-existent; hence, a research agenda is proposed.
Keywords Africa . Latin America . Psoriasis . Spondyloarthritis . Treatment
Introduction
Psoriatic arthritis (PsA) is a spondyloarthritis that affects
up to a third of patients with psoriasis, a common in-
flammatory skin disease affecting 1–3% of the popula-
tion [2]. The heterogeneous disease manifestations make
management of PsA a challenge [3]. The Group for
Research and Assessment of Psoriasis and Psoriatic
Arthritis (GRAPPA) and the European League Against
Rheumatism (EULAR) have updated their respective
recommendations [4, 5] for the management of PsA.
These recommendations are based on systematic reviews
of literature and provide evidence-based recommenda-
tions for the management of PsA. However, they are
primarily based on studies conducted in resource replete
countries of Europe and North America; therefore, they
may not be applicable to PsA patients in resource-poor
countries in the Americas excluding Canada and the
USA- (henceforth termed ‘the Americas’) and Africa.
To address this gap, our objective was to adapt the
published GRAPPA and EULAR recommendations for
the management of PsA to resource-poor settings using
the ADAPTE process [6].
Methods and results
Under the auspices of the International League of
Associations for Rheumatology (ILAR), we aimed to cre-
ate recommendations for the management of PsA in
resource-poor settings. The recommendations were
targeted at clinicians caring for PsA patients more than
16 years of age residing in the Americas or Africa. The
target audience for these recommendations includes rheu-
matologists, dermatologists, internists, primary care prac-
titioners, patients and other stakeholders practicing or liv-
ing in the Americas or Africa. The Asia-Pacific region was
not included since the Asia Pacific League of Associations
for Rheumatology (APLAR) is also developing similar
recommendations.
ADAPTE process
Assembly of the organizing committee
An organizing committee of 8 rheumatologists with experi-
ence in PsA treatment recommendations and/or practice in
resource-poor settings was established. The committee
consisted of rheumatology experts, researchers, and active
GRAPPA members. The committee decided to use the
ADAPTE process to develop the new recommendations.
The ADAPTE Collaboration [1] defines guideline adaptation
as the systematic approach to considering the use and/or mod-
ification of (a) guideline(s) produced in one cultural and orga-
nizational setting for application in a different context. The




One hundred and thirty-four potential participants (rheumatol-
ogists and dermatologist, GRAPPA and some non-GRAPPA
members of the Panamerican League of Associations for
Rheumatology (PANLAR), the African League Against
Rheumatism (AFLAR), and Asia-Pacific League of
Associations for Rheumatology (APLAR) regions) were invit-
ed by the organizing committee to participate in an initial email
survey. Members from the APLAR region were invited to pro-
vide input since they had experience in treating PsA in similar
resource-poor settings. The objectives were to identify specific
challenges in their local practice particularly access to special-
ists, access to therapies, infectious diseases, and any specific
comorbidities that may influence management of PsA.
Seventy-nine respondents (57 rheumatologists and 22 der-
matologists) completed the survey, of whom 16 were from
Africa and 46 were from the Americas. Respondents were
invited to be members of the recommendation panel. Thirty-
six participants provided an affirmative response, but only 15
participants completed the project (10 rheumatologists and 5
dermatologists). The entire task force of this project
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represented five countries in the Americas, four countries in
Africa, and four countries from other regions.
Based on the responses and a face-to-face meeting held at
the annual GRAPPA meeting in 2017, the committee and the
panel members identified three areas of interest to be included
in the adapted recommendations: (a) efficacy and safety of
pharmacotherapy, (b) recommendations for physicians with
limited access to other specialists, (c) screening and manage-
ment of tuberculosis (TB), hepatitis B/C virus infection (HB/
CV), human immunodeficiency virus (HIV) disease, Chagas’
disease, leishmaniasis, and leprosy. Subsequently, members
selected their area(s) of interest to work on; thus, three work-
ing groups were formed.
Phase two: adaptation
Determining the health questions
After having identified the areas of interest, members of the
committee drafted the PIPOH criteria and the health questions
which was used as a tool (Table 1):
& P Patient population (including disease characteristics)
& I Intervention of interest
& P Professionals/patients (audience for whom the guideline
is prepared)
& OOutcomes to be taken into consideration (purpose of the
guideline)
& H Healthcare setting and context
The drafted PIPOH criteria and the health questions were
disseminated via email to the entire task force for refinement.
Three Patient Research Partners from the Americas also par-
ticipated in this task. The PIPOH criteria and 18 questions
developed are shown in Tables 1 and 2, respectively.
Screening source recommendations
The source recommendations were assessed on their clinical
content according to the health questions formulated. We
modified the ADAPTE tool 8: Table for Summarizing
Guideline Content to prepare a table in which participants of
each working group were asked whether an answer was stated
in the source recommendations and their degree of agreement
with that answer if available. After an iterative process, ten
questions reached < 70% of agreement. To answer these ques-
tions, a systematic review of literature from the Americas and
Africa was conducted.
Search for other documents: systematic literature review
The systematic search included the following databases:
Medline, Embase, African Index Medicus (AIM), Cochrane
Central, and Literatura Latino Americana en Ciencias de la
Salud (Latin-American Literature in Health Science-
LILACS); and literature identified by the panel of participants.
Inclusion criteria were: (1) Randomized controlled trials, (2)
observational studies, (3) case series, (4) resource-poor set-
tings in the Americas or Africa, and (5) any language.
Exclusion criteria were: (1) review articles, (2) abstracts, (3)
conference proceedings, (4) case report.
A systematic review to update the source recommendations
was not performed since it would have been outside the scope
of our objective. After duplicates were removed, articles were
selected through a screening process based first on the title,
second on abstract and third on the full-text review (Fig. 1).
Articles were retrieved if their content was relevant to the
health questions framed by the PIPOH definition for this pro-
ject. Three authors carried out the data extraction
independently.
The search identified 8135 articles. Of these, 24 were iden-
tified for full review and data extraction (Fig. 1). Despite this
Table 1 PIPOH criteria for
developing the health questions Population PsA patients of at least 16 years of age living in the Americas or Africa, particularly
those with specific comorbidities of interest(TB, HIV, HB/CV, Chagas’ disease,
leishmaniasis and leprosy)
Intervention -Screening for: TB, HIV, HB/CV, Chagas’ disease, leishmaniasis, and leprosy prior to
pharmacotherapy
-Adverse events during pharmacotherapy
-Treatment: duration and type: sequential/combination, according to domains
-Response evaluation
-Supportive care-Follow up
Professionals/patient Rheumatologists, dermatologists, internists, primary care physicians, other stakeholders,
patients
Outcome -Patient Outcomes: Drug Efficacy, adverse events
-Access to specialists and multidisciplinary care
Health care setting Hospitals, clinics, doctor’s offices, primary care.
HIV human immunodeficiency virus, HB/CV hepatitis B or C virus, PsA psoriatic arthritis, TB tuberculosis
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exhaustive systematic literature review (SLR), there were sev-
eral health questions for this project that were not addressed
by evidence retrieved. These included questions related to the
safety of combinations of conventional synthetic disease-
modifying anti-rheumatic drugs (csDMARDs) and biologic
disease-modifying anti-rheumatic drugs (bDMARDs) in gen-
eral and in areas with endemic infections, the frequency of
monitoring of individuals on therapy in resource-poor settings
and recommendations for dermatologists treating PsAwithout
rheumatology support or vice versa.
Given the availability and use of biosimilar and intended
copies, our search also included studies on the use of this
group of drugs in PsA. One review article addressed this topic
but unfortunately did not offer a clear conclusion due to a lack
of evidence. When investigating the safety screening required
for csDMARD or bDMARD therapy in PsA, nine studies
were identified that reported screening for infectious diseases.
None of these studies were reported exclusively in PsA pa-
tients and none were RCTs. The majority looked into TB
screening (n = 8) and showed that tuberculin skin test and
chest radiographs are widely used as screening tests, but the
best method is still debated particularly in endemic areas.
Concerning the use of bDMARDs, 14 studies were identi-
fied that examined bDMARD use on patients in the Americas
or Africa. These studies identified successful use of
bDMARDs in areas of endemic infection, but limited data
included meant that no recommendations different from the
current ones could be made. Studies around treatment of co-
morbidities in PsA did not identify specific literature from the
Americas or Africa.
Assessment of guideline quality
The quality of the GRAPPA and EULAR source recommen-
dations was evaluated with the Appraisal of Guidelines for
Research and Evaluation II (AGREE II) Instrument [7] (avail-
able at http://www.agreetrust.org/). AGREE II Instrument
evaluates the process of practice guideline development and
the quality of reporting by using the AGREE Reporting
Checklist [8]. This instrument includes 23 items that are
organized into six domains: 1. scope and purpose; 2.
stakeholder involvement; 3. rigor of development; 4. clarity
of presentation; 5. applicabili ty; and 6. editorial
independence. Each of the 23 items targets various aspects of
practice guideline quality. Each item is scored on a scale
ranging from 1 (“strongly disagree”) to 7 (“strongly agree”).
Each source recommendation was independently assessed by
two reviewers who upon the completion of those 23 items also
provided 2 additional overall assessments of the guideline: the
overall quality of the recommendation scored again from 1 to 7
and a recommendation about its use by selecting the ‘Yes’ or
‘Yes with modifications’ or ‘No’ options provided. We used
the raw AGREE scores to determine agreement amongst the
appraisers on various items of the AGREE domains (Fig. 2).
Assess applicability
The applicability of the principles contained in the source
recommendations was assessed using Tool 15-Evaluation
Sheet-Acceptability/Applicability. According to ADAPTE’s
definition of acceptability and applicability, “Acceptable” in-
dicates that it should be put it into practice, and ‘Applicable’
indicates that physicians are able to put it into practice. A table
Table 2 Health questions (those marked with an asterisk* did not have
sufficient evidence within the source recommendations and were
included in the SLR)
Efficacy/adverse events of drug treatment
1. What are the goals of therapy?
2. Assessments (history, physical, laboratory and radiological) of
patients, including the presence of extra articular manifestations, to
achieve goals of therapy
3. Efficacy of pharmacotherapy in all PsA domains and in the presence
of extra articular manifestations
4. Safety of pharmacotherapy in PsA
5. Efficacy of combination therapy
6. Safety of combination therapy*
7. Frequency of laboratory monitoring*
8. Safety and efficacy of biosimilars and intended copies*
Recommendations for Rheumatologists with limited access to
Dermatologists and vice versa*
1. Recommendations to rheumatologist/internists for treatment of
psoriasis particularly those with limited access to support from
dermatologists
2. Recommendations to dermatologists for treatment of psoriatic
arthritis particularly those with limited access to support from
rheumatologists?
3. Recommendations for combined multidisciplinary team
4. Availability of allied health and social support: social work,
physiotherapy, occupational therapy
TB, HB/CV, HIV, and other infections
1. Screening for TB prior to therapy with bDMARDs*
2. Recommendations for the management of the increased risk of TB
with bDMARDs in high TB endemic areas*
3. Recommendations on the management of infection with TB, HIV,
and HB/CV in patients receiving bDMARDs*
4. Safety of combination of bDMARDs and csDMARDs (higher risk of
TB, HIV, HB/CV, Chagas’ disease, leishmaniasis, leprosy)*
5. Screening and management of HB/CV, HIV, Chagas’ disease,
leishmaniasis, leprosy*
Assessing comorbidities and CV risk
1. Considerations for treatment of patients with psoriatic arthritis and
concomitant comorbidities*
bDMARDs biological DMARD, csDMARDs conventional synthetic
DMARDs, such as methotrexate, sulfasalazine, or leflunomide;
DMARDs disease-modifying anti-rheumatic drugs, HIV human immuno-
deficiency virus, HB/CV hepatitis B/C virus, PsA psoriatic arthritis, TB
tuberculosis
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was sent to the committee members to assess the acceptability
of each principle in terms of our target population, benefits to
this population, and its compatibility with the culture and
values of the population, and to assess the applicability of each
principle in terms of availability of the intervention, expertise,
legal and resource constraints. They were provided with three
options: Accept as is, modify, or reject principle for further
discussion (for an example see Appendix 2).
Principles from both source guidelines with a score of more
than 80% in the “accept as is” option of the acceptability and
applicability items were taken as overarching principles for
the adapted ILAR recommendations.
Adaptation of the principles and the recommendations
GRAPPA and EULAR PsA treatment recommendations
are recent guidelines with strong methodological quality
from where principles and recommendations were adapted
to produce ILAR PsA treatment recommendations for
resource-poor countries. Members of the organizing com-
mittee summarized principles and recommendations from
the source recommendations, and the supporting evidence
of the SLR to address each health question and their appli-
cability to the context of use according to the assessments
previously described.
Fig. 2 AGREE II Instrument:
Appraisal of Guidelines for
Research Evaluation II. Each
guideline was reviewed by two
independent appraisers
Fig. 1 Preferred Reporting Items




inclusion. The search terms
included PsA, the Americas,
Africa, and infectious diseases.
Studies included from database
inception until February 22 2018
well as literature sent by the panel.
The search strategy and MESH
terms are provided in Appendix 1
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Principles
The principles are shown in Table 3. Those were selected
according to their acceptability and applicability with an
agreement of more than 80%.
Recommendations
Recommendations are shown in Table 4. Those were selected
if their clinical content provided answers to the health ques-
tions formulated and if they reached a consensus of more than
70%. Where available, data from the literature search was
used for unanswered health questions. However due to a lack
of data, expert opinion was sought for the answers not found
in the SLR. Although specific data were not found relating to
treatment in the presence of comorbidities, this was felt to be
important in all healthcare settings. Thus, the comorbidities
table highlighting potential risks and benefits to comorbidities
with different therapies taken from the GRAPPA recommen-
dations was included (Table 5).
Phase three: finalization
External review and acknowledgment
After the recommendations were adapted the document
was sent for external review to a dermatologist from the
Americas and a rheumatologist from Africa for review.
Feedback was solicited using the ADAPTE feedback ques-
tionnaire and free text. Overall the recommendations were
supported and found to be beneficial. Given the inclusion
of targeted therapies in the management of PsA, one re-
viewer felt that the recommendations were too expensive
to apply given poor access to these drugs in some settings.
They highlighted a relative lack of data to support the pro-
cess and suggested a research agenda to be included within
this recommendation (Table 6).
Approval by endorsing bodies
These recommendations are adapted from the GRAPPA and
EULAR published recommendations and we acknowledge
Fig. 3 GRAPPA treatment schema, recommendations for each domain.
©2016, American College of Rheumatology. With permission from John
Wiley and Sons. GRA PPA treatment schema for active psoriatic arthritis
(PsA). Light text identifies conditional recommendations for drugs that
do not currently have regulatory approvals or for which recommendations
are based on abstract data only. CS corticosteroid, vit vitamin, CSA
cyclosporine A, DMARDs disease-modifying antirheumatic drugs, IA
intraarticular, IL-12/23i interleukin-12/23 inhibitor, LEF leflunomide,
MTX methotrexate, NSAIDs nonsteroidal anti-inflammatory drugs,
PDE-4i phosphodiesterase 4 inhibitor (apremilast), phototx
phototherapy, SpA spondyloarthritis, SSZ sulfasalazine, TNFi tumor
necrosis factor inhibitor
1844 Clin Rheumatol (2020) 39:1839–1850
these source documents [4, 5]. Following development of this
manuscript, source guideline developers were consulted for
feedback.
Plan for review and update
The management of PsA is a rapidly evolving field with
a number of new medications approved since the 2015
recommendations and further drugs currently in devel-
opment. As EULAR and GRAPPA update their recom-
mendations, these recommendations should also undergo
periodic update.
Discussion
The Institute of Medicine defines clinical guidelines as “sys-
tematically developed statements to assist practitioner and pa-
tient decisions about appropriate health care for specific clin-
ical circumstances [9]. Hence, we aimed to adapt the most
recently published GRAPPA and EULAR recommendations
for the management of PsA for resource-poor settings. We
followed the ADAPTE process and formulated PIPOH ques-
tions and conducted a systematic review of literature address-
ing these questions where it was not addressed by the source
recommendations. However, evidence from the literature to
answer the questions was weak or non-existent forcing us to
resort to expert opinion. A research agenda in order to spur
research into gaps in knowledge about management of PsA in
resource-poor settings was formulated.
This process used published treatment recommendations
for PsA, a heterogeneous disease affecting the skin and mus-
culoskeletal structures, which have been developed and re-
vised by GRAPPA [4] and EULAR [5], and most recently
by the American College of Rheumatology [10]. However,
these recommendations were developed based on data obtain-
ed largely in resource-replete settings and are more easily
applicable to advanced economies. The applicability of these
recommendations to resource-poor settings is questionable.
We chose to use the ADAPTE process and adapt existing
recommendations rather than develop new recommendations.
We believed that developing new recommendations from
available literature would not be efficient since the current
recommendations are based on review of recent developments
in the field and are unlikely to be significantly different. We,
therefore, chose to review the literature from the Americas and
Africa to address questions relevant to management of PsA in
resource-poor settings. Unfortunately, there is very little re-
search done in resource-poor settings to address important
practical questions about the management of PsA in the
Americas and Africa.
We were able to engage rheumatologists and dermatolo-
gists as well as patients in developing these recommendations.
The PIPOH questions were developed mainly by practitioners
and patients from the Americas and Africa and their input was
crucial in providing expert opinion for the adapted recommen-
dations. The strong collaborative effort across continents sets
the stage for designing studies to address unmet needs using
the research networkwe have developed through this exercise.
The recommendations demonstrate that the goals of treat-
ment, assessment of disease and associated comorbidities, and
principles of safety and follow up are similar to the source
recommendations. However, the type and severity of comor-
bidities are likely to be different in resource-poor settings. It is
believed that the burden of concomitant infectious diseases
such as TB, HB/CV, HIV, Chagas’ disease, and leishmaniasis
is likely to be higher although high-quality studies showing
Table 3 Principles
A. Goals of therapy
The ultimate goals of therapy for all patients with PsA are as follows: 1)
To achieve the lowest possible level of disease activity in all domains of
disease; as definitions of remission and low or minimal disease activity
become accepted, these will be included in the goal. 2) To optimize
functional status, improve quality of life and well-being, and prevent
structural damage to the greatest extent possible. 3) To avoid or
minimize complications, both from untreated active disease and from
therapy (GRAPPA principle 1).
B. Assessment of domains
Assessment of patients with PsA requires consideration of all major
disease domains, including peripheral arthritis, axial disease, enthesitis,
dactylitis, psoriasis, and nail disease. The impact of disease on pain,
function, quality of life, and structural damage should be examined. In
addition, activity in other potential related conditions should be
considered, included cardiovascular disease, uveitis and, bowel disease.
Multidisciplinary and multispecialty assessment and management will
be most beneficial for individual patients. (GRAPPA principle 2)
PsA is a heterogeneous and potentially severe disease, which may
require multidisciplinary treatment (EULAR principle A)
C. Assessment of relevant comorbidities
A comprehensive assessment of relevant comorbidities (including but
not restricted to obesity, metabolic syndrome, gout, diabetes,
cardiovascular disease, liver disease, depression, and anxiety) should be
undertaken and documented. (GRAPPA principle 4)
When managing patients with PsA, extra-articular manifestations,
metabolic syndrome, cardiovascular disease and other comorbidities
should be taken into account. (EULAR principle E)
D. Safety of pharmacotherapy and shared decision making
Therapeutic decisions need to be individualized, and are made jointly
by the patient and his or her doctor. Treatment should reflect patient
preferences, with the patients provided with the best information and
relevant options provided to them. Treatment choices may be affected
by various factors, including disease activity, structural damage,
comorbid conditions, and previous therapies. (GRAPPA principle 5)
Treatment of patients with PsA should aim at the best care and must be
based on a shared decision between the patient and the rheumatologist,
considering efficacy, safety and costs. (EULAR principle B)
E. Frequency of follow-up
Ideally, patients should be reviewed promptly, offered regular
evaluation by appropriate specialists, and have treatment adjusted as
needed in order to achieve the goals of therapy. Early diagnosis and
treatment is likely to be of benefit.(GRAPPA principle 6)
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high prevalence in PsAwere lacking. Given the likelihood of
adverse outcomes with newer immunomodulatory therapy,
studies evaluating the safety and efficacy of these drugs in
resource-poor settings are required but are currently lacking
(and/or) are of poor quality. Pragmatic interventional and ob-
servational trials with the newer agents in resource-poor set-
tings will benefit clinical decision-making and are on the re-
search agenda.
Likewise, the prevalence of chronic disease is also rising in
resource-poor settings [11]. Thus the management of PsA and
associated non-communicable as well as infection-related co-
morbidities is challenging and will need to be addressed in
future research studies given the lack of literature. We have
provided expert opinion and acknowledge its inherent
limitations.
One major unanswered question in the management of PsA
is the safety and efficacy of combination therapy.
Combination therapy (with multiple csDMARDs or a
Table 4 Recommendations
1. Goals of therapy
1. Treatment should be aimed at reaching the target of remission or,
alternatively, minimal/low disease activity, by regular monitoring and
appropriate adjustment of therapy. In PsA, there exist few data regarding
natural history, treatment objectives and remission. However, since in PsA
inflammation is related to long-term outcomes of joint involvement, this
recommendation states that the objective in patients with PsA is remission
or if remission cannot be achieved, a low orminimal disease activity state.
Remission is defined here as the absence of clinical and laboratory
evidence of significant inflammatory disease activity. In addition to
absence of inflammation in the joints, absence of enthesitis and dactylitis
are also important. It should be noted that this remission of inflammation
may not equate to complete absence of all symptoms for many patients.
Indeed, recent work in PsA demonstrated that the impact of the disease on
quality of life is related to pain, skin problems and functional disability,
and fatigue, as well as emotional and social aspects of impact. Some of
these aspects of impact may be less accessible to pharmacological
therapies of PsA, thus leading to a ‘residual’ impact in the absence of
inflammation. Furthermore, remission may be difficult to achieve in PsA.
Factors associated with higher remission rates appear to be younger age,
lower functional impairment and higher C reactive protein levels in some
cases. Remission is still insufficiently defined in PsA.We suggest that the
use of outcomes where remission/low disease activity have been defined,
should be considered. This is now the case for several scores used in PsA,
some of which focus only on arthritis whereas others encompass various
aspects of psoriatic disease. As regards joint involvement, a stringent
remission definition and criteria for low disease activity by the Disease
Activity index for Psoriatic Arthritis (DAPSA) have been recently defined
and validated. However, minimal/low disease may also be a relevant
target especially for long-standing disease, as stringent remission may not
be achievable in these patients or in some patients with comorbidities that
preclude escalation of therapy. Minimal disease activity in PsA has been
defined as five of the seven criteria comprising musculoskeletal and skin
manifestations and patient-reported outcomes. This outcome has been
shown in one study to be predictive of less structural degradation, and in
the recent Tight control in PsA (TICOPA) trial to be a valid treatment
target. Definitions of remission and acceptable residual disease activity
levels in PsA, its predictors and its relationship with long-term outcomes
are still a part of the research agenda and more thorough assessment of
prognostic markers of severity (related to risk of progressive disease,
structural damage, physical disability and quality of life) must still be
addressed. (EULAR recommendation 1)
2. Screening and management of TB, HIV, HB/CV, Chagas’ disease,
leishmaniasis, leprosy, and other concomitant comorbidities
GRAPPA treatment of PsA and concomitant comorbidities. See Table 5.
Since the SLR did not find evidence to make recommendations, expert
opinion is provided. Given the endemic nature of TB, HIV, HBV/HCV,
Chagas’ disease, leishmaniasis, leprosy, and other infectious diseases,
it is recommended that appropriate screening for prevalent infections
be conducted as per local and national guidelines prior to initiation of
immunosuppressive therapies (especially bDMARDs). Periodically
thereafter and ideally at each clinical encounter careful assessment for
active infection should be conducted to avoid serious, life threatening
infectious complications.
3. Frequency of monitoring
Since the SLR did not find evidence to make recommendations, expert
opinion is provided. Patients need to be evaluated periodically to assess
response to therapy and identify complications and adverse events. The
frequency of monitoring should depend on the time to expected
response when starting a new csDMARD/bDMARD and the degree of
disease activity. Less frequent follow up may be acceptable when
disease is well controlled, and changes in therapy are not anticipated.
Table 4 (continued)
4. Safety and efficacy of pharmacotherapy in all domains
GRAPPA treatment schema, recommendations for each domain. See
Fig.3.
Since the SLR did not find evidence to make recommendations about
safety of bDMARDs in TB endemic areas, expert opinion is provided.
We recommend that the GRAPPA recommendations on treatment be
followed although we recognize that access to many therapies,
especially bDMARDs may be difficult in resource poor settings.
Appropriate screening for endemic disease such as tuberculosis (such
as chest X-ray and Mantoux or IGRAs) prior to therapy and periodic
evaluation during therapy with bDMARDs, especially TNFi agents as
per local guidelines are recommended.
5. Efficacy and safety of combination therapy
Recent data suggest that continuation of a concomitant csDMARD
therapy in combination with TNFis is beneficial in PsA in terms of
treatment maintenance and levels of response, especially in patients
using monoclonal antibodies, but more data are warranted including
the effect of concomitant csDMARD on immunogenicity. (EULAR
recommendation 5)
Since the SLR did not find evidence to make recommendations, expert
opinion is provided. The efficacy and safety of combination of biologic
therapy with csDMARDs as well as combination with tsDMARD
therapy is not well established. Such therapy may be used carefully
with frequent monitoring of response and adverse events, especially
organ toxicity and infections.
6. Safety and efficacy of biosimilars and intended copies
Since the SLR did not find evidence to make recommendations, expert
opinion is provided. Use of biosimilars may be considered in the
management of psoriatic arthritis with careful monitoring of adverse
events, especially infections, as recommended when using
bDMARDs. We do not recommend the use of intended copies, until
proper evaluation of their efficacy and safety.
bDMARDs biological DMARD, csDMARDs conventional synthetic
DMARDs, such asmethotrexate, sulfasalazine, or leflunomide;DMARDs
disease-modifying anti-rheumatic drugs, tsDMARDs targeted synthetic
DMARDs, HIV human immunodeficiency virus, HB/CV hepatitis B/C
virus, PsA psoriatic arthritis, SLR systematic literature review, TB tuber-
culosis, TNFi tumor necrosis factor inhibitors, GRAPPA Group for
Research and Assessment of Psoriasis and Psoriatic Arthritis, EULAR
European League Against Rheumatism
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Table 5 GRAPPA treatment of PsA and concomitant comorbidities. © 2016, American College of Rheumatology. With permission from John Wiley and Sons
NSAIDs CS HCQ SSZ MTX LEF CSA Etanercept Adalimumab Infliximab CZP Golimumab Ustekinumab Apremilast
Cardiovascular disease C ? NI NI NI NI NI NI NI NI NI NI NI NI
Congestive heart failure C C NI NI NI NI NI C C C C C NI NI
Obesity NI NI NI NI C NI NI NI NI NI NI NI NI NI
Metabolic syndrome NI C NI NI C NI NI NI NI NI NI NI NI NI
Diabetes NI C NI NI C NI NI NI NI NI NI NI NI NI
Ulcerative colitis ? NI NI A NI NI OL NI A A NI A NI NI
Crohn’s disease ? NI NI A OL NI NI NI A A A NI NI NI
Uveitis NI P† NI NI NI NI NI ? P P NI NI NI NI
Osteoporosis NI C NI NI NI NI NI NI NI NI NI NI NI NI
Malignancy NI NI NI NI NI NI NI C C C C C ? NI
Fatty Liver disease C NI NI C C C NI NI NI NI NI NI NI NI
Chronic kidney disease C NI NI NI C ? SM NI NI NI NI NI NI NI
Depression NI NI NI NI NI NI NI NI NI NI NI NI NI ?
Chronic hepatitis B Ŧ C NI NI NI C C NI SM SM SM SM SM ? NI
Chronic hepatitis C Ŧ C NI NI NI C C NI ?/P ? ? ? ? ? NI
HIV NI NI NI NI NI NI NI SM SM SM SM SM ? NI
A approved for primary therapy of the comorbid condition, C reason for caution, CS corticosteroids, CSA cyclosporine A, CZP certolizumab pegol, HCQ hydroxychloroquine, LEF leflunomide, NI no
information available, OL off-label use for therapy of the comorbid condition, P preferred therapy, SM requires special monitoring, SSZ sulfasalazine
? data insufficient but concerns have been raised.
† Corticosteroids used as preferred therapy for uveitis are most commonly given as topical and/or intraocular injections in preference to oral steroids.



















combination of csDMARDS and bDMARDs) is often used by
clinicians in resource-replete as well as resource-poor settings
but the evidence for efficacy and safety (especially with co-
morbidities) is lacking. Similarly, biosimilars and intended
copies are increasingly available and being used with limited
evidence about its safety and efficacy in patients with PsA.
This is particularly relevant in the resource-poor setting where
access to costly newer medications is poor and hence combi-
nation therapy or use of intended copies is likely to be more
frequent in PsA resistant to monotherapy. Further research in
this area is of utmost importance. One related clinical question
is also how frequently to monitor patients. This is primarily a
question of resources since the doctor-patient ratio and the
resources for conducting laboratory tests are grossly inade-
quate in most countries. An efficient and cost-effective model
is required but is yet to be developed. Moreover, educational
programs to guide rheumatologists in the management of pso-
riasis when access to a dermatologist is poor, and to a derma-
tologist for the management of PsAwhen access to a rheuma-
tologist or internist is difficult may improve care of PsA in
these settings.
We did not include studies from the Asia-Pacific region in
this exercise since APLAR was developing their own recom-
mendations. However, we intend to collaborate with re-
searchers and clinicians from that region to develop country
or region-specific recommendations and share best practices.
Moreover, we did not include the most recent American
College of Rheumatology/National Psoriasis Foundation
guidelines for the treatment of PsA [10] or the most recent
update of the EULAR PsA treatment recommendations since
these recommendations were published only after our litera-
ture review and guideline appraisals were completed.
Thus, the ILARTreatment Recommendations for PsAwere
developed through the collaborative effort of researchers and
clinicians from the Americas including Canada, Africa, and
the UK. These recommendations intend to serve as reference
for the management of PsA in resource-poor settings in the
Americas and Africa. This paper illustrates the experience of
an international working group in adapting existing recom-
mendations to resource-poor setting. It highlights the need to
conduct research on the management of PsA in these regions,
sets a research agenda and intends to form the basis to conduct
collaborative clinical research on the management of PsA in
resource-poor settings.
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Table 6 Research Agenda for
PsA in resource-poor countries to
fill the gaps in the ILAR
recommendations
1. Goals of therapy • Outcomes of treatment of PsA by specialists compared
to general practitioners
2. Screening and management of TB, HIV, HB/CV,
Chagas’ disease, leishmaniasis, leprosy, and other
concomitant comorbidities
• Cost effective screening strategy for TB, HIV, HB/CV,
Chagas’ disease, leishmaniasis and leprosy
• Prevalence of TB, HIV, HB/CV, Chagas’ disease,
leishmaniasis, leprosy in patients with PsA
• Risk of worsening or new onset TB, HIV, HB/CV,
Chagas’ disease, leishmaniasis, leprosy on treatment
with csDMARDs or bDMARDs in PsA
• Risk of worsening or new onset TB, HIV, HB/CV,
Chagas’ disease, leishmaniasis, leprosy on treatment
with bDMARDs in PsA
• Effect of cardiovascular and related comorbidities on
achieving treatment outcome in PsA
3. Frequency of monitoring in resource poor
countries
• Cost effective frequency of disease
assessment/monitoring in PsA
4. Safety and efficacy of pharmacotherapy in all
domains
• Safety and efficacy of csDMARDs in resource-poor
settings
• Safety and efficacy of bDMARDs in resource-poor
settings
5. Safety and efficacy of combination therapy • Safety and efficacy of combination csDMARDs or
bDMARDs in resource-poor settings
6. Safety and efficacy of biosimilars and intended
copies
• Safety and efficacy of biosimilars in resource-poor
settings
bDMARDs biological DMARDs,DMARD disease-modifying anti-rheumatic drug,HIV human immunodeficien-
cy virus. HB/CV hepatitis B/C virus, PsA psoriatic arthritis, TB tuberculosis
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